Table 2.
Baseline characteristics of participants a.
| Reference | Study Type | Sample Size | Age (Year) b | Female (%) | Cancer Type | Treatment | Sarcopenia (%) |
|---|---|---|---|---|---|---|---|
| Adams et al. [23] | RCT | 200 | 48.8 (25.0–78.0) |
100 | Breast cancer (Early stages: I to IIIa) |
Receiving adjuvant chemotherapy | 25.5 (25.0% class I; 0.5% class II) |
| Yamamoto et al. [24] | Quasi-experimental | 22 | 75.0 ± 5.0 | 54.5 | Gastric cancer (All stages) |
Scheduled gastrectomy (pre-operative) |
100 |
| Dawson et al. [25] | Pilot RCT | 37 | 63.7 ± 8.3 | 0 | Prostate cancer (All stages) |
Receiving ADT | 43.8 |
| Dieli-Conwright et al. [26] | RCT | 100 | 53.5 ± 10.4 | 100 | Breast cancer (Early stages: I to III) |
Completed treatment < 6 months (chemotherapy and/or radiotherapy) |
Not reported |
| Koya et al. [27] | Quasi-experimental | 209 | 74.7 (69.0–79.6) c |
35.4 | HCC (All stages) |
Treated with TACE | Not reported |
| Moug et al. [28] | RCT | 44 | 66.8 ± 9.6 | 36 | Rectal cancer (Stage not reported) |
Receiving neoadjuvant chemoradiotherapy | 14 |
| Delrieu et al. [29] | Quasi-experimental | 47 | 55 ± 10.4 | 100 | Breast cancer (Metastatic) |
Receiving any combination of chemotherapy, radiotherapy, hormonal therapy and targeted therapy | 53.2 |
a ADT = androgen deprivation therapy; HCC = hepatocellular carcinoma; NA = not applicable; RCT = randomized clinical trial; TACE = transcatheter arterial chemoembolization. b Unless otherwise stated, ages are presented as mean ± standard deviation or mean (range). c Median (IQR).